Latest filing published 03 Jul 2023 for OncoCyte Corp.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
John Peter Gutfreund: trading record in brief
John Peter Gutfreund discloses dealings in Insight Molecular Diagnostics Inc. to SEC (Form 4). Over a trading history stretching from 15 August 2022 to 30 June 2023, the count stands at 6 filings.
No open-market sale appears; the market trades are 2 purchases worth €46k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 3 share grants.
The newest entry dates from 3 July 2023: a transaction, in Insight Molecular Diagnostics Inc. The clock since the last published purchase (28 December 2022) now reads 1,413 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to John Peter Gutfreund
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,085,047 shares0Common Stock, no par valueSEC:0000899243-23-016837:0
- 705,000 shares@ US$0.354490.8% of flowCommon Stock, no par valueSEC:0001493152-23-011106:0
- 75,000 shares@ US$0.32979.2% of flowCommon Stock, no par valueSEC:0001493152-22-036653:0Canonical exit: 23 Mar 2023 (T+90)
- 10,000 shares0Common Stock, no par valueSEC:0001493152-22-023380:0
4 of 4 declarations
